휴마시스
205470KOSDAQ의료용품 및 기타 의약 관련제품 제조업63.0 / 100
Reference Date: 2026-06-10
Company InformationBased on 2025 Annual Report
Business Overview
HumaSys operates in three main business segments: POCT immunoassay reagents for in vitro diagnostics, production of male condoms and medical devices, and entertainment services. The POCT division focuses on improving diagnostic products for COVID-19 and HIV, while the rubber products division produces a range of items according to international standards. The entertainment division generates revenue through artist management and content production. Major revenue streams come from POCT (13.4%), rubber products (19.5%), and entertainment services (46.2%).
Number of Employees
64people
Average Salary
47.6M KRW
Score Calculation Basis
Detailed Financial Score
Half of industry avg (excellent)
1.8x industry avg (good)
Half of industry avg (excellent)
Avg ▲51.1% (2-year basis)
Avg ▲39.9% (2-year basis)
Avg ROE -13.2% (improving, 3yr)
Detailed News Sentiment
- Neutral빌리언스, 스페이스X 공급망 트리스 투자…우주 신사업 속도
빌리언스의 트리스 인수는 우주항공 분야에 대한 투자 확대를 시사하지만, 휴마시스와 직접적인 연관성이 없어 중립적 평가.
Detailed Momentum
52w mid range (59%)
1m +252.68% (strong rise)
Volume dry-up
Detailed Disclosure
- Neutral주식등의대량보유상황보고서(일반)2026-06-05
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-05
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-05-29
- Neutral주식등의대량보유상황보고서(일반)2026-05-29
- Neutral주식등의대량보유상황보고서(일반)2026-05-22
